An experimental drug cocktail has been found to eradicate Hepatitis C after six weeks of therapy.

Achillion Pharmacutical Inc’s hepatitis C drug, when used together with Gilead Sciences Inc’s Sovaldi, removed viral signs after six weeks.

Related Article: Government seeks pharmacists' views to underpin first-ever men’s health strategy

This result bettered Gilead’s own hepatitis C treatment which managed the same amount of viral reduction after eight weeks.

Achillion’s ongoing mid-stage study is aiming to achieve a sustained virological response 12 weeks after therapy, which is considered a cure.

It was achieved by using a 50mg dose of Achillion’s NS5a inhibitor in combination with 400mg of Gileads’ sofosbuvir in previously untreated genotype 1 hepatitis C patients.

Related Article: Prescription charge to stay at £9.90 for May

Achillion CEO Milind Deshpande said the data represents the “shortest duration and highest response” achieved with any two drug, direct acting antiviral regime for hepatitis C.

It is claimed hepatitis C affects 150m people worldwide.

Related Article: Recognition that NI GP pharmacist pay 'does not fully align' with AfC

Almost 50% of people who inject drugs in England are believed to have the disease. Hepatitis C is usually transmitted through blood to blood contact - through sharing razors, toothbrushes or sharing unsterilised needles.